[
  {
    "ts": null,
    "headline": "AbbVie raises full-year forecast, Newell Brands stock plunges",
    "summary": "Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including AbbVie (ABBV) shares sliding as the company raises its annual forecast on the success of its anti-inflammatory drugs, while Sharpie-parent company Newell Brands (NWL) stock plunges after cutting its full-year outlook on a challenging consumer environment tied to tariff price hikes. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=d4272d2ca37abf42f1623a827b6f17031490be78dfb785ee4e589584a8709dd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761934114,
      "headline": "AbbVie raises full-year forecast, Newell Brands stock plunges",
      "id": 137279087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including AbbVie (ABBV) shares sliding as the company raises its annual forecast on the success of its anti-inflammatory drugs, while Sharpie-parent company Newell Brands (NWL) stock plunges after cutting its full-year outlook on a challenging consumer environment tied to tariff price hikes. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=d4272d2ca37abf42f1623a827b6f17031490be78dfb785ee4e589584a8709dd2"
    }
  },
  {
    "ts": null,
    "headline": "Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window",
    "summary": "Corbus Pharmaceuticals Holdings pivots CRB-701 focus to rare cancers with promising early results. Click for key CRBP stock updates, risks and growth prospects.",
    "url": "https://finnhub.io/api/news?id=6015dc83c7c7609dbe30f9c6fd3b4f7a2553124fe0750808a6b9b30100175cd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761931723,
      "headline": "Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window",
      "id": 137282415,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221989856/image_2221989856.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Corbus Pharmaceuticals Holdings pivots CRB-701 focus to rare cancers with promising early results. Click for key CRBP stock updates, risks and growth prospects.",
      "url": "https://finnhub.io/api/news?id=6015dc83c7c7609dbe30f9c6fd3b4f7a2553124fe0750808a6b9b30100175cd2"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie (ABBV) Shares Are Falling Today",
    "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a reduced earnings forecast for the full year. Although AbbVie's quarterly revenue of $15.78 billion and adjusted earnings per share (EPS) of $1.86 both surpassed Wall Street's estimates, investors focused on underlying weaknesses. The company's operating margin fell sharply to 12.1% from 26.5% a year a",
    "url": "https://finnhub.io/api/news?id=fc47f09e219cbaf9e6fd5a1ce6f97091220bb58c93778a59552af34e50794d9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761930144,
      "headline": "Why AbbVie (ABBV) Shares Are Falling Today",
      "id": 137278863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a reduced earnings forecast for the full year. Although AbbVie's quarterly revenue of $15.78 billion and adjusted earnings per share (EPS) of $1.86 both surpassed Wall Street's estimates, investors focused on underlying weaknesses. The company's operating margin fell sharply to 12.1% from 26.5% a year a",
      "url": "https://finnhub.io/api/news?id=fc47f09e219cbaf9e6fd5a1ce6f97091220bb58c93778a59552af34e50794d9e"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=26dc2c19b37ba30da6680c5ed9fbf7d620da5631680a2c31444648b7d8378f8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761908940,
      "headline": "Health Care Roundup: Market Talk",
      "id": 137277251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=26dc2c19b37ba30da6680c5ed9fbf7d620da5631680a2c31444648b7d8378f8c"
    }
  },
  {
    "ts": null,
    "headline": "Dow Is Hovering Around Breakeven",
    "summary": "The Dow was struggling to stay above breakeven despite Amazon stock’s best efforts on Friday. The blue-chip index was moving in and out of negative territory. The S&P 500 was up 0.3%. The Nasdaq Composite was up 0.",
    "url": "https://finnhub.io/api/news?id=4358d0fecb8bd56eddb63ac9ef2f33fc499c063a5f9b3676d5df15878885c393",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761926494,
      "headline": "Dow Is Hovering Around Breakeven",
      "id": 137278893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Dow was struggling to stay above breakeven despite Amazon stock’s best efforts on Friday. The blue-chip index was moving in and out of negative territory. The S&P 500 was up 0.3%. The Nasdaq Composite was up 0.",
      "url": "https://finnhub.io/api/news?id=4358d0fecb8bd56eddb63ac9ef2f33fc499c063a5f9b3676d5df15878885c393"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript",
    "summary": "AbbVie Inc. (ABBV) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert...",
    "url": "https://finnhub.io/api/news?id=69e08ad097a382ab8ab105b233623a4c9b5b8558909ce09a5f959bfd6f8cdd7d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761926183,
      "headline": "AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript",
      "id": 137281701,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (ABBV) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert...",
      "url": "https://finnhub.io/api/news?id=69e08ad097a382ab8ab105b233623a4c9b5b8558909ce09a5f959bfd6f8cdd7d"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Amazon Shares Rise After Strong Earnings; Apple Fiscal Q4 Results Beat Estimates",
    "summary": "All three major US stock indexes were up in late-morning trading Friday as investors digested strong",
    "url": "https://finnhub.io/api/news?id=e1e52b55ad0738dd053b5244bb99a5dafd3af46d7323e86c48087f7c1a676301",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761925012,
      "headline": "Top Midday Stories: Amazon Shares Rise After Strong Earnings; Apple Fiscal Q4 Results Beat Estimates",
      "id": 137278924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Friday as investors digested strong",
      "url": "https://finnhub.io/api/news?id=e1e52b55ad0738dd053b5244bb99a5dafd3af46d7323e86c48087f7c1a676301"
    }
  },
  {
    "ts": null,
    "headline": "Reddit, AbbVie, Western Digital: Earnings in focus",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Reddit's (RDDT) stock surging after releasing strong third quarter revenue and advertising sales forecasts, AbbVie (ABBV) shares slumping on mixed drug sales in its third quarter, and Western Digital (WDC) topping its earnings expectations. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=e49fc9322e801692b546b209e49f635cd9426aa9b8341ab10ad69cfc15efd5b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761923291,
      "headline": "Reddit, AbbVie, Western Digital: Earnings in focus",
      "id": 137279092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Reddit's (RDDT) stock surging after releasing strong third quarter revenue and advertising sales forecasts, AbbVie (ABBV) shares slumping on mixed drug sales in its third quarter, and Western Digital (WDC) topping its earnings expectations. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=e49fc9322e801692b546b209e49f635cd9426aa9b8341ab10ad69cfc15efd5b3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
    "summary": "While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=0b131b3ff7f4c73a72259ece5f68980d241276e36a7f3001419858dfd532ed39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761922802,
      "headline": "AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
      "id": 137279093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=0b131b3ff7f4c73a72259ece5f68980d241276e36a7f3001419858dfd532ed39"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Lifts Outlook Even as Humira, Imbruvica Weakness Limits Quarterly Revenue Growth",
    "summary": "AbbVie (ABBV) raised its full-year outlook even as weakness in its Humira rheumatoid arthritis medic",
    "url": "https://finnhub.io/api/news?id=7ff4b3ba0430f1c91cd33777ed3b5e866124b1fc0c4a3cf5370e913c0004ea2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761922627,
      "headline": "AbbVie Lifts Outlook Even as Humira, Imbruvica Weakness Limits Quarterly Revenue Growth",
      "id": 137279094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) raised its full-year outlook even as weakness in its Humira rheumatoid arthritis medic",
      "url": "https://finnhub.io/api/news?id=7ff4b3ba0430f1c91cd33777ed3b5e866124b1fc0c4a3cf5370e913c0004ea2a"
    }
  },
  {
    "ts": null,
    "headline": "Demographic Megatrend: Stocks Poised to Benefit From Global Aging",
    "summary": "Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.",
    "url": "https://finnhub.io/api/news?id=2b367ca0fca3393f3bdea85762cdbcf46c42c9eb9ffbc799caabac0ef05ed58a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761922260,
      "headline": "Demographic Megatrend: Stocks Poised to Benefit From Global Aging",
      "id": 137279095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.",
      "url": "https://finnhub.io/api/news?id=2b367ca0fca3393f3bdea85762cdbcf46c42c9eb9ffbc799caabac0ef05ed58a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates",
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +5.08% and +1.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=d33e6dc7ca6e515ea9f3604c8fbd6ceeb917a9a3b15c4e46229be5b81275ece6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761915602,
      "headline": "AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates",
      "id": 137279096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +5.08% and +1.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=d33e6dc7ca6e515ea9f3604c8fbd6ceeb917a9a3b15c4e46229be5b81275ece6"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Lifts Profit Outlook as Sales Rise",
    "summary": "AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.",
    "url": "https://finnhub.io/api/news?id=84812d709c24d7eee00cb95e19f02d309d1962fdc250c4f0b98bfc2285c8e6c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761914520,
      "headline": "AbbVie Lifts Profit Outlook as Sales Rise",
      "id": 137277314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.",
      "url": "https://finnhub.io/api/news?id=84812d709c24d7eee00cb95e19f02d309d1962fdc250c4f0b98bfc2285c8e6c4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie quarterly profit drops on costs but ups 2025 outlook, dividend",
    "summary": "AbbVie quarterly profit drops on costs but ups 2025 outlook, dividend",
    "url": "https://finnhub.io/api/news?id=7a58f9f7e0eac7166a99c95dbbac726b5792c56bff2142ea59d805ba4d127d0b",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761913841,
      "headline": "AbbVie quarterly profit drops on costs but ups 2025 outlook, dividend",
      "id": 137276888,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7a58f9f7e0eac7166a99c95dbbac726b5792c56bff2142ea59d805ba4d127d0b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie lifts full-year profit outlook amid strong psoriasis drug demand",
    "summary": "Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.",
    "url": "https://finnhub.io/api/news?id=8233e26a9f888fea6f5af5aa6d4777fa9f18e9a5d8ed063f9afaea259a26af47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761913708,
      "headline": "AbbVie lifts full-year profit outlook amid strong psoriasis drug demand",
      "id": 137277315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.",
      "url": "https://finnhub.io/api/news?id=8233e26a9f888fea6f5af5aa6d4777fa9f18e9a5d8ed063f9afaea259a26af47"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%",
    "summary": "AbbVie dipped early Friday, though the drug giant easily beat third-quarter forecasts on the back of its immunology meds.",
    "url": "https://finnhub.io/api/news?id=8b993b560caa3d3d977d6a946ce68f21623d72ac8d81f125d49e265292561177",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761913349,
      "headline": "AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%",
      "id": 137277316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie dipped early Friday, though the drug giant easily beat third-quarter forecasts on the back of its immunology meds.",
      "url": "https://finnhub.io/api/news?id=8b993b560caa3d3d977d6a946ce68f21623d72ac8d81f125d49e265292561177"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.",
    "summary": "FEATURE   AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.",
    "url": "https://finnhub.io/api/news?id=05775eb82c527aaf9b53fc389dbdf8ae36f1b928160854392932d9f0a156ab6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761913200,
      "headline": "AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.",
      "id": 137277301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "FEATURE   AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.",
      "url": "https://finnhub.io/api/news?id=05775eb82c527aaf9b53fc389dbdf8ae36f1b928160854392932d9f0a156ab6b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=97383fc54f4f13da91511ebd86f2819a85a7f6c28b636c64867469e1cd532e92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761912690,
      "headline": "AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates",
      "id": 137277318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=97383fc54f4f13da91511ebd86f2819a85a7f6c28b636c64867469e1cd532e92"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Q3 Earnings Snapshot",
    "summary": "ABBV) on Friday reported third-quarter net income of $186 million. On a per-share basis, the North Chicago, Illinois-based company said it had net income of 10 cents. Earnings, adjusted for amortization costs and asset impairment costs, were $1.86 per share.",
    "url": "https://finnhub.io/api/news?id=2f605b527be15bd550ad729accb3eb4c0e71692fad8c6c67a7911159d5917f84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761911920,
      "headline": "AbbVie: Q3 Earnings Snapshot",
      "id": 137277319,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV) on Friday reported third-quarter net income of $186 million. On a per-share basis, the North Chicago, Illinois-based company said it had net income of 10 cents. Earnings, adjusted for amortization costs and asset impairment costs, were $1.86 per share.",
      "url": "https://finnhub.io/api/news?id=2f605b527be15bd550ad729accb3eb4c0e71692fad8c6c67a7911159d5917f84"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Reports Third-Quarter 2025 Financial Results",
    "summary": "AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025.",
    "url": "https://finnhub.io/api/news?id=e6f54d4dd0419ff831ddb392ccc2156de54d829c959dadb6314ede570cb146d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761911340,
      "headline": "AbbVie Reports Third-Quarter 2025 Financial Results",
      "id": 137277320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025.",
      "url": "https://finnhub.io/api/news?id=e6f54d4dd0419ff831ddb392ccc2156de54d829c959dadb6314ede570cb146d8"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Mostly Up Pre-Bell as Traders Parse Apple, Amazon Earnings",
    "summary": "The benchmark US stock measures were mostly pointing higher before the open Friday as traders digest",
    "url": "https://finnhub.io/api/news?id=f6b8b82c573ab61a6d58c87dac4bca867d836bacf47f83ae55869e210b78b96b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761909773,
      "headline": "Stocks Mostly Up Pre-Bell as Traders Parse Apple, Amazon Earnings",
      "id": 137277145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The benchmark US stock measures were mostly pointing higher before the open Friday as traders digest",
      "url": "https://finnhub.io/api/news?id=f6b8b82c573ab61a6d58c87dac4bca867d836bacf47f83ae55869e210b78b96b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Why Q3 Confirms Its Immunology Dominance",
    "summary": "AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=2cf08acf8bffde47895303fb70bac1b045d034f90b9bbef370a803bda96f3cba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761907191,
      "headline": "AbbVie: Why Q3 Confirms Its Immunology Dominance",
      "id": 137277814,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/939034648/image_939034648.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=2cf08acf8bffde47895303fb70bac1b045d034f90b9bbef370a803bda96f3cba"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie raises its annual forecast despite sluggish quarterly earnings",
    "summary": "AbbVie has reported Q3 2025 adjusted net income of $3.31bn, down 38% year-on-year. Adjusted EPS reached $1.86, compared to $3.00 a year earlier.On a reported basis, net income was $186m, a fraction -...",
    "url": "https://finnhub.io/api/news?id=68b358127a179dcfe35a0ff5b3e9b7a69d04168ad68bfa7d711df69a70ceb9fe",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761904287,
      "headline": "AbbVie raises its annual forecast despite sluggish quarterly earnings",
      "id": 137277598,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie has reported Q3 2025 adjusted net income of $3.31bn, down 38% year-on-year. Adjusted EPS reached $1.86, compared to $3.00 a year earlier.On a reported basis, net income was $186m, a fraction -...",
      "url": "https://finnhub.io/api/news?id=68b358127a179dcfe35a0ff5b3e9b7a69d04168ad68bfa7d711df69a70ceb9fe"
    }
  },
  {
    "ts": null,
    "headline": "Exxon Mobil, Berkshire Earnings and Fed Speakers: Still to Come This Week",
    "summary": "Investors will tune into earnings from oil majors Chevron and Exxon Mobil on Friday. Here’s what to watch for: Today   Earnings: AbbVie, Chevron (read more), Colgate-Palmolive, Exxon Mobil.   Federal Reserve speakers: Lorie Logan, Beth Hammack and Raphael Bostic are due to speak at a conference on bank funding in Dallas.",
    "url": "https://finnhub.io/api/news?id=5b519eca301a131229c7d1259391ced2213f6643dcf43048ccd2db83cf9e3397",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761899640,
      "headline": "Exxon Mobil, Berkshire Earnings and Fed Speakers: Still to Come This Week",
      "id": 137277277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investors will tune into earnings from oil majors Chevron and Exxon Mobil on Friday. Here’s what to watch for: Today   Earnings: AbbVie, Chevron (read more), Colgate-Palmolive, Exxon Mobil.   Federal Reserve speakers: Lorie Logan, Beth Hammack and Raphael Bostic are due to speak at a conference on bank funding in Dallas.",
      "url": "https://finnhub.io/api/news?id=5b519eca301a131229c7d1259391ced2213f6643dcf43048ccd2db83cf9e3397"
    }
  }
]